AVTX - Why Microcap Biotech Firm Avalo Therapeutics Stock Is Trading Higher Today? | Benzinga
Avalo Therapeutics Inc (NASDAQ: AVTX) shares are trading higher after the company agreed to sell its rights, title, and interest in assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) to AUG Therapeutics.
AUG will pay an upfront payment of $150,000, as well as, for each compound, make a contingent milestone payment of $15 million (for a potential aggregate of $45 million) if the first FDA approval is ...